BeyondSpring Pharmaceuticals, Inc. (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small-molecule therapeutics for the treatment of cancer. Leveraging proprietary technology platforms, the company focuses on targeting the tumor microenvironment, innate immunity and key cellular pathways to address unmet needs in oncology. BeyondSpring’s research approach combines vascular-disrupting agents with immunotherapy to enhance anti-tumor efficacy and patient outcomes.
The company’s lead asset, plinabulin (BPI-2358), is a selective immunomodulating microtubule-binding agent designed to improve chemotherapy tolerance and simultaneously stimulate the body’s innate immune response. In parallel, BeyondSpring is advancing seribantumab (BAY 2731952), an anti-HER3 monoclonal antibody, in combination trials for various solid tumors. Additional preclinical programs explore next-generation modulators of immune checkpoints and novel targets within the tumor microenvironment.
BeyondSpring operates out of research and development facilities in the United States and China, with headquarters in Princeton, New Jersey, and Shanghai. The company collaborates with leading academic institutions and global biopharmaceutical partners to accelerate clinical development across North America, Europe and Asia. These alliances support multi-regional trials and aim to streamline regulatory pathways for potential global approvals.
Founded in 2017, BeyondSpring is led by a management team with extensive experience in oncology drug development, regulatory affairs and commercialization. Under the leadership of President and Chief Executive Officer Peony Low, the organization continues to build a diversified pipeline and pursue strategic collaborations to bring transformative cancer therapies to patients worldwide.
AI Generated. May Contain Errors.
